HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript

Company Overview - HUTCHMED is presenting at Deutsche Bank's Virtual Investor Conference, highlighting its innovative drug FRUZAQLA [1][2] - The company has experienced significant growth, with FRUZAQLA sales increasing by 25% in the first half of the year [4] Leadership and Team - David Ng serves as the Head of Investor Relations and Capital Strategies for HUTCHMED, accompanied by Matthew Kwong, VP of Finance [2] Future Direction - The presentation aims to provide insights into HUTCHMED's past performance, current status, and future direction, emphasizing the company's commitment to global commercial success [4]